Growing the love for investing
Results 1 - 10 of 747 : 1 2 3 4 5 6 7 8 9 Next
Get RSS Feed for Pharmaceuticals
Another Alzheimer's Disease Failure
Eli Lilly stops phase 2 trial of BACE inhibitor after some Alzheimer's patients had abnormal liver biochemical tests.
AstraZeneca's Buying Spree Bolsters Pipeline
A string of recent acquisitions means AstraZeneca is taking a proactive approach to giving its pipeline life.
The Stock Picker's Guide to AstraZeneca
A structured analysis of AstraZeneca.
What Are the City's Expectations for AstraZeneca's Profits?
How might earnings at AstraZeneca change in the years to come?
Can This Experimental Drug Be Brought Back From the Dead?
Written off for dead in 2009, this drug may show increased efficacy at higher doses.
AstraZeneca to Spend Up to $1.15 Billion on New Acquisition
AstraZeneca announces the purchase of an American developer of asthma treatments.
Why You Should Care About This Diabetes Drug Saga
Are changes to Glaxo's Avandia a sign that the FDA is lightening up?
Clinical data, licensing, and layoffs -- oh, my!
How AstraZeneca Measures Up as a GARP Investment
How do AstraZeneca's growth prospects stack up?
AstraZeneca Writes Off $140 Million Following Product Trial
AstraZeneca admits that trials of a treatment for rheumatoid arthritis did not meet expectations.
BATS data provided in real-time. NYSE, NASDAQ and NYSEMKT data delayed 15 minutes.
Real-Time prices provided by BATS. Market data provided by Interactive Data.
Company fundamental data provided by Morningstar. Earnings Estimates, Analyst Ratings and Key Statistics provided by Zacks.
SEC Filings and Insider Transactions provided by Edgar Online.
Powered and implemented by Interactive Data Managed Solutions. Terms & Conditions
RSS Headlines
Fool UK